187 related articles for article (PubMed ID: 17045649)
1. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
Aribi A; Huh Y; Keating M; O'brien S; Ferrajoli A; Faderl S; Wierda W; Kantarjian H; Ravandi F
Leuk Res; 2007 Jul; 31(7):939-45. PubMed ID: 17045649
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
Au WY; Lam CC; Chim CS; Pang AW; Kwong YL
Leuk Res; 2005 Oct; 29(10):1213-5. PubMed ID: 16111536
[TBL] [Abstract][Full Text] [Related]
3. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
4. T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature.
Osuji N; Matutes E; Tjonnfjord G; Grech H; Del Giudice I; Wotherspoon A; Swansbury JG; Catovsky D
Cancer; 2006 Aug; 107(3):570-8. PubMed ID: 16795070
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia.
Rosenblum MD; LaBelle JL; Chang CC; Margolis DA; Schauer DW; Vesole DH
Blood; 2004 Mar; 103(5):1969-71. PubMed ID: 14976065
[No Abstract] [Full Text] [Related]
6. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
7. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
[TBL] [Abstract][Full Text] [Related]
9. Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment.
Osuji N; Matutes E; Wotherspoon A; Catovsky D
Leuk Res; 2005 Feb; 29(2):225-8. PubMed ID: 15607372
[TBL] [Abstract][Full Text] [Related]
10. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
12. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
Nabhan C; Gartenhaus RB; Tallman MS
Leuk Res; 2004 May; 28(5):429-42. PubMed ID: 15068894
[TBL] [Abstract][Full Text] [Related]
13. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
[TBL] [Abstract][Full Text] [Related]
14. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Dearden CE; Matutes E; Catovsky D
Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
[TBL] [Abstract][Full Text] [Related]
15. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
Lee SS; Robinson MR; Morris JC; Mirtsching BC; Shen D; Chan CC
Surv Ophthalmol; 2004; 49(5):525-36. PubMed ID: 15325197
[TBL] [Abstract][Full Text] [Related]
16. Current treatment options in prolymphocytic leukemia.
Robak T; Robak P
Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
[TBL] [Abstract][Full Text] [Related]
17. Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocyte leukemia.
Evans HL; Burks E; Viswanatha D; Larson RS
Hum Pathol; 2000 Oct; 31(10):1266-73. PubMed ID: 11070120
[TBL] [Abstract][Full Text] [Related]
18. What choices are available for treatment of the patient with chronic lymphocytic leukemia who is fludarabine-refractory?
Byrd JC; Rai KR
Semin Oncol; 2000 Aug; 27(4):xii-xv; discussion xv-xvi. PubMed ID: 10950363
[No Abstract] [Full Text] [Related]
19. Large granular lymphocyte leukemia: natural history and response to treatment.
Fortune AF; Kelly K; Sargent J; O'Brien D; Quinn F; Chadwick N; Flynn C; Conneally E; Browne P; Crotty GM; Thornton P; Vandenberghe E
Leuk Lymphoma; 2010 May; 51(5):839-45. PubMed ID: 20367569
[TBL] [Abstract][Full Text] [Related]
20. Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.
Monjanel H; Hourioux C; Arbion F; Colombat P; Lissandre S; Regner MP; Senecal D
Leuk Res; 2010 Aug; 34(8):e197-9. PubMed ID: 20211489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
